Parkinson's disease and cardiovascular involvement: Edifying insights (Review)
- Authors:
- Laura Grosu
- Alin Ionut Grosu
- Dana Crisan
- Alexandru Zlibut
- Lacramioara Perju-Dumbrava
-
Affiliations: Department of Neurology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania, Department of Internal Medicine, 5th Medical Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania - Published online on: February 14, 2023 https://doi.org/10.3892/br.2023.1607
- Article Number: 25
-
Copyright: © Grosu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Pohar SL and Allyson Jones C: The burden of Parkinson disease (PD) and concomitant comorbidities. Arch Gerontol Geriatr. 49:317–321. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H and Wang Z: Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Front Public Health. 9(776847)2021.PubMed/NCBI View Article : Google Scholar | |
|
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, et al: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet. 392:1789–1858. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, Culpepper WJ, Dorsey ER, Elbaz A, Ellenbogen RG, et al: Global, regional, and national burden of neurological disorders, 1990-2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol. 18:459–480. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A and Joly P: Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France. Mov Disord. 33:1449–1455. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Scorza FA, Fiorini AC, Scorza CA and Finsterer J: Cardiac abnormalities in Parkinson's disease and Parkinsonism. J Clin Neurosci. 53:1–5. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Noack C, Schroeder C, Heusser K and Lipp A: Cardiovascular effects of levodopa in Parkinson's disease. Parkinsonism Relat Disord. 20:815–818. 2014.PubMed/NCBI View Article : Google Scholar | |
|
van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C and Schoors D: Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 363:1179–1183. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Kho J, Ioannou A, Mandal AKJ and Missouris CG: Donepezil induces ventricular arrhythmias by delayed repolarisation. Naunyn Schmiedebergs Arch Pharmacol. 394:559–560. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Palma JA and Kaufmann H: Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 33:372–390. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Coon EA, Cutsforth-Gregory JK and Benarroch EE: Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 33:349–358. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chen Z, Li G and Liu J: Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 134(104700)2020.PubMed/NCBI View Article : Google Scholar | |
|
Arici Duz O and Helvaci Yilmaz N: Nocturnal blood pressure changes in Parkinson's disease: Correlation with autonomic dysfunction and vitamin D levels. Acta Neurol Belg. 120:915–920. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sommer S, Aral-Becher B and Jost W: Nondipping in Parkinson's disease. Parkinsons Dis. 2011(897586)2011.PubMed/NCBI View Article : Google Scholar | |
|
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS and de Bie RMA: Prevalence of orthostatic hypotension in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 17:724–729. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Yalcin A, Atmis V, Cengiz OK, Cinar E, Aras S, Varli M and Atli T: Evaluation of cardiac autonomic functions in older Parkinson's disease patients: A cross-sectional study. Aging Dis. 7:28–35. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Palma JA and Kaufmann H: Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 4:298–308. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Jain S and Goldstein DS: Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiol Dis. 46:572–580. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Senard JM, Raï S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A and Montastruc JL: Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry. 63:584–589. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Blaho A, Šutovský S, Valkovič P, Šiarnik P, Sýkora M and Turčáni P: Decreased baroreflex sensitivity in Parkinson's disease is associated with orthostatic hypotension. J Neurol Sci. 377:207–211. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nakamura T, Hirayama M, Hara T, Mizutani Y, Suzuki J, Watanabe H and Sobue G: Role of cardiac sympathetic nerves in preventing orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord. 20:409–414. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Shibata M, Morita Y, Shimizu T, Takahashi K and Suzuki N: Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci. 276:79–83. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Goldstein DS: Dysautonomia in Parkinson's disease: Neurocardiological abnormalities. Lancet Neurol. 2:669–676. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Goldstein DS, Pechnik S, Holmes C, Eldadah B and Sharabi Y: Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 42:136–142. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Galvin JE, Lee VMY and Trojanowski JQ: Synucleinopathies: Clinical and pathological implications. Arch Neurol. 58:186–190. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Iodice V, Low DA, Vichayanrat E and Mathias CJ: Cardiovascular autonomic dysfunction in MSA and Parkinson's disease: Similarities and differences. J Neurol Sci. 310:133–138. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Cuoco S, Carotenuto I, Cappiello A, Scannapieco S, Russillo MC, Andreozzi V, Forino L, Amboni M, Picillo M, Erro R, et al: Relationship between orthostatic hypotension and cognitive functions in multiple system atrophy: A longitudinal study. Front Neurol. 12(711358)2021.PubMed/NCBI View Article : Google Scholar | |
|
de la Sierra A, Gorostidi M, Banegas JR, Segura J, de la Cruz JJ and Ruilope LM: Nocturnal hypertension or nondipping: Which is better associated with the cardiovascular risk profile? Am J Hypertens. 27:680–687. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M and Lang AE: Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: Prioritisation of treatment targets. Lancet Neurol. 15:954–966. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shin NY, Park YW, Yoo SW, Yoo JY, Choi Y, Jang J, Ahn KJ, Kim BS and Kim JS: Adverse effects of hypertension, supine hypertension, and perivascular space on cognition and motor function in PD. NPJ Parkinsons Dis. 7(69)2021.PubMed/NCBI View Article : Google Scholar | |
|
Meade RM, Fairlie DP and Mason JM: Alpha-synuclein structure and Parkinson's disease-lessons and emerging principles. Mol Neurodegener. 14(29)2019.PubMed/NCBI View Article : Google Scholar | |
|
Javanshiri K, Drakenberg T, Haglund M and Englund E: Cardiac alpha-synuclein is Present in alpha-synucleinopathies. J Parkinsons Dis. 12:1125–1131. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Isonaka R, Rosenberg AZ, Sullivan P, Corrales A, Holmes C, Sharabi Y and Goldstein DS: Alpha-synuclein deposition within sympathetic noradrenergic neurons is associated with myocardial noradrenergic deficiency in neurogenic orthostatic hypotension. Hypertension. 73:910–918. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rodrigues LD, Oliveira LF, Shinoda L, Scorza CA, Faber J, Ferraz HB, Britto LRG and Scorza FA: Cardiovascular alterations in rats with Parkinsonism induced by 6-OHDA and treated with Domperidone. Sci Rep. 9(8965)2019.PubMed/NCBI View Article : Google Scholar | |
|
Tijero B, Gómez-Esteban JC, Lezcano E, Fernández-González C, Somme J, Llorens V, Martínez A, Ruiz-Martínez J, Foncea N, Escalza I, et al: Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene. Parkinsonism Relat Disord. 19:95–100. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Tijero B, Gómez Esteban JC, Somme J, Llorens V, Lezcano E, Martinez A, Rodríguez T, Berganzo K and Zarranz JJ: Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord. 19:906–909. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Park JH, Kim DH, Park YG, Kwon DY, Choi M, Jung JH and Han K: Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: A nationwide, population-based cohort study. Circulation. 141:1205–1207. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Suri JS, Paul S, Maindarkar MA, Puvvula A, Saxena S, Saba L, Turk M, Laird JR, Khanna NN, Viskovic K, et al: Cardiovascular/stroke risk stratification in Parkinson's disease patients using atherosclerosis pathway and artificial intelligence paradigm: A systematic review. Metabolites. 12(312)2022.PubMed/NCBI View Article : Google Scholar | |
|
Driver JA, Kurth T, Buring JE, Gaziano JM and Logroscino G: Parkinson disease and risk of mortality: A prospective comorbidity-matched cohort study. Neurology. 70:1423–1430. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Nam GE, Kim SM, Han K, Kim NH, Chung HS, Kim JW, Han B, Cho SJ, Yu JH, Park YG and Choi KM: Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med. 15(e1002640)2018.PubMed/NCBI View Article : Google Scholar | |
|
Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, Jousilahti P and Tuomilehto J: Association of blood pressure and hypertension with the risk of Parkinson disease: The national FINRISK study. Hypertension. 57:1094–1100. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Liang HW, Huang YP and Pan SL: Parkinson disease and risk of acute myocardial infarction: A population-based, propensity score-matched, longitudinal follow-up study. Am Heart J. 169:508–514. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Potashkin J, Huang X, Becker C, Chen H, Foltynie T and Marras C: Understanding the links between cardiovascular disease and Parkinson's disease. Mov Disord. 35:55–74. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Vikdahl M, Carlsson M, Linder J, Forsgren L and Håglin L: Weight gain and increased central obesity in the early phase of Parkinson's disease. Clin Nutr. 33:1132–1139. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S, Gan-Or Z and Noyce AJ: Type 2 diabetes as a determinant of Parkinson's disease risk and progression. Mov Disord. 36:1420–1429. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hassan A, Sharma Kandel R, Mishra R, Gautam J, Alaref A and Jahan N: Diabetes mellitus and Parkinson's disease: Shared pathophysiological links and possible therapeutic implications. Cureus. 12(e9853)2020.PubMed/NCBI View Article : Google Scholar | |
|
Athauda D and Foltynie T: Insulin resistance and Parkinson's disease: A new target for disease modification? Prog Neurobiol. 145-146:98–120. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lương K and Nguyễn L: Role of vitamin D in Parkinson's disease. ISRN Neurol. 2012(134289)2012.PubMed/NCBI View Article : Google Scholar | |
|
Kim JS, Kim YI, Song C, Yoon I, Park JW, Choi YB, Kim HT and Lee KS: Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci. 20:495–498. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Pascale E, Purcaro C, Passarelli E, Guglielmi R, Vestri AR, Passarelli F and Meco G: Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. J Neurol Sci. 276:18–21. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Castellani R, Smith MA, Richey GL and Perry G: Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 737:195–200. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Soós J, Engelhardt JI, Siklós L, Havas L and Majtényi K: The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport. 15:1715–1718. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Choi JM, Hong JH, Chae MJ, Hung NP, Kang HS, Ma HI and Kim YJ: Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neurosci Lett. 493:97–101. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Fullard ME and Duda JE: A review of the relationship between vitamin D and Parkinson disease symptoms. Front Neurol. 11(454)2020.PubMed/NCBI View Article : Google Scholar | |
|
Pignolo A, Mastrilli S, Davì C, Arnao V, Aridon P, Dos Santos Mendes FA, Gagliardo C and D'Amelio M: Vitamin D and Parkinson's disease. Nutrients. 14(1220)2022.PubMed/NCBI View Article : Google Scholar | |
|
Barichella M, Garrì F, Caronni S, Bolliri C, Zocchi L, Macchione MC, Ferri V, Calandrella D and Pezzoli G: Vitamin D status and Parkinson's disease. Brain Sci. 12(790)2022.PubMed/NCBI View Article : Google Scholar | |
|
Rizzoni D, Rizzoni M and Nardin M: Vitamin D and ischaemic heart disease: A casual or A causal association?: Commentary on: ‘Raslan E et al. Association of vitamin D deficiency with chronic stable angina: A case-control study’. High Blood Press Cardiovasc Prev. 26:151–155. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Wang W, Tan Z, Zhu X, Liu M, Wan R and Hong K: The relationship between vitamin D and risk of atrial fibrillation: A dose-response analysis of observational studies. Nutr J. 18(73)2019.PubMed/NCBI View Article : Google Scholar | |
|
Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, Yelangi A, Sundus S, Bachuwa G, Alkotob ML and Manson JE: Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: A Meta-analysis. JAMA Cardiol. 4:765–776. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Luan Y and Yao Y: The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol. 9(1302)2018.PubMed/NCBI View Article : Google Scholar | |
|
Qiu X, Xiao Y, Wu J, Gan L, Huang Y and Wang J: C-reactive protein and risk of Parkinson's disease: A systematic review and meta-analysis. Front Neurol. 10(384)2019.PubMed/NCBI View Article : Google Scholar | |
|
Sawada H, Oeda T, Umemura A, Tomita S, Kohsaka M, Park K, Yamamoto K and Sugiyama H: Baseline C-reactive protein levels and life prognosis in Parkinson disease. PLoS One. 10(e0134118)2015.PubMed/NCBI View Article : Google Scholar | |
|
Hwang O: Role of oxidative stress in Parkinson's disease. Exp Neurobiol. 22:11–17. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Perfeito R, Cunha-Oliveira T and Rego AC: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med. 53:1791–1806. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, et al: Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 66:1460–1468. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I and Ascherio A: Parkinson Study Group PRECEPT Investigators. Hyson C, et al: Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 65:716–723. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bluett B, Togasaki DM, Mihaila D, Evatt M, Rezak M, Jain S, Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, et al: Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial. JAMA. 326:926–939. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Borghi C and Piani F: Uric acid and risk of cardiovascular disease: A question of start and finish. Hypertension. 78:1219–1221. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Saito Y, Shioya A, Sano T, Sumikura H, Murata M and Murayama S: Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. Mov Disord. 31:135–138. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F and Hashimoto M: Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett. 425:18–22. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Lev N, Roncevich D, Ickowicz D, Melamed E and Offen D: Role of DJ-1 in Parkinson's disease. J Mol Neurosci. 29:215–226. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Repici M and Giorgini F: DJ-1 in Parkinson's disease: Clinical insights and therapeutic perspectives. J Clin Med. 8(1377)2019.PubMed/NCBI View Article : Google Scholar | |
|
Shimizu Y, Nicholson CK, Polavarapu R, Pantner Y, Husain A, Naqvi N, Chin LS, Li L and Calvert JW: Role of DJ-1 in modulating glycative stress in heart failure. J Am Heart Assoc. 9(e014691)2020.PubMed/NCBI View Article : Google Scholar | |
|
Tsoporis JN, Drosatos IA, Gupta S, Amatullah H, Izhar S, Dos Santos CC, Salpeas V, Rigopoulos AG, Toumpoulis IK, Triantafyllis AS, et al: Cytoprotective mechanisms of DJ-1: Implications in cardiac pathophysiology. Molecules. 26(3795)2021.PubMed/NCBI View Article : Google Scholar | |
|
He R, Yan X, Guo J, Xu Q, Tang B and Sun Q: Recent advances in biomarkers for Parkinson's disease. Front Aging Neurosci. 10(305)2018.PubMed/NCBI View Article : Google Scholar | |
|
Cuenca-Bermejo L, Almela P, Navarro-Zaragoza J, Fernández Villalba E, González-Cuello AM, Laorden ML and Herrero MT: Cardiac changes in Parkinson's disease: Lessons from clinical and experimental evidence. Int J Mol Sci. 22(13488)2021.PubMed/NCBI View Article : Google Scholar | |
|
Dhall R and Kreitzman DL: Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 86 (14 Suppl 1):S13–S24. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Günaydin ZY, Özer FF, Karagöz A, Bektaş O, Karataş MB, Vural A, Bayramoğlu A, Çelik A and Yaman M: Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment. J Geriatr Cardiol. 13:75–80. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C and Blandini F: Homocysteine and Parkinson's disease: A dangerous liaison? J Neurol Sci. 257:31–37. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Kocer B, Guven H and Comoglu SS: Homocysteine levels in Parkinson's disease: Is entacapone effective? Biomed Res Int. 2016(7563705)2016.PubMed/NCBI View Article : Google Scholar | |
|
O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T and Diaz-Arrastia R: Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations. Arch Neurol. 61:865–868. 2004.PubMed/NCBI View Article : Google Scholar | |
|
van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C and Schoors D: Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 61:859–861. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, et al: Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord. 19:656–662. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Tran T, Brophy JM, Suissa S and Renoux C: Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson's disease: A systematic review of observational studies. CNS Drugs. 29:985–998. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kho J, Ioannou A, Mandal AKJ, Cox A, Nasim A, Metaxa S and Missouris CG: Long term use of donepezil and QTc prolongation. Clin Toxicol (Phila). 59:208–214. 2021.PubMed/NCBI View Article : Google Scholar | |
|
de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC and van Dalen EC: Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 9(CD014638)2022.PubMed/NCBI View Article : Google Scholar | |
|
Mei M, Zhou Y, Liu M, Zhao F, Wang C, Ding J, Lu M and Hu G: Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 160(107758)2019.PubMed/NCBI View Article : Google Scholar |
